Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak

Ulla Feldt-Rasmussen, Georg Brabant, Dominique Maiter, Björn Jonsson, Andy Toogood, Maria Koltowska-Haggstrom, Åse Krogh Rasmussen, Michael Buchfelder, Bernhard Saller, Beverly M K Biller

    14 Citations (Scopus)

    Abstract

    We studied whether the severity of GH deficiency (GHD) defined as i) GH-peak on stimulation tests (insulin tolerance test (ITT), arginine, and glucagon), ii) number of additional pituitary deficits, or iii) baseline IGF1 SDS could impact the response to GH treatment. We further explored whether iv) IGF1 SDS after 24 months of GH replacement or v) ΔIGF1 SDS from baseline to 24 months was related to the phenotypic response to GH treatment. DESIGN, PATIENTS, AND MEASUREMENTS: The patient cohort (n=1752; 50% women) was obtained from KIMS (Pfizer International Metabolic Database). The patients were divided into three groups of approximately equal size (tertiles) according to the stimulated GH-peak values and baseline IGF1 SDS and were studied at baseline, 12, and 24 months of GH therapy.
    Original languageEnglish
    JournalEuropean Journal of Endocrinology
    Volume168
    Issue number5
    Pages (from-to)733-43
    Number of pages11
    ISSN0804-4643
    DOIs
    Publication statusPublished - May 2013

    Keywords

    • Adult
    • Age Factors
    • Aged
    • Blood Pressure
    • Body Weight
    • Cholesterol
    • Databases, Factual
    • Female
    • Hormone Replacement Therapy
    • Human Growth Hormone
    • Humans
    • Hypopituitarism
    • Insulin-Like Growth Factor I
    • Male
    • Middle Aged
    • Quality of Life
    • Sex Factors
    • Treatment Outcome
    • Triglycerides

    Fingerprint

    Dive into the research topics of 'Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak'. Together they form a unique fingerprint.

    Cite this